Related Experiment Video
Updated: Jun 27, 2026
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Targeted therapies in breast cancer: where are we now?
Serena Di Cosimo1, José Baselga
1Medical Oncology Program, Medical Oncology Department, Vall d'Hebron University Hospital, Passeig Vall d'Hebron, Barcelona, Spain.
Abstract:
Over the past several years significant advances have been made in our understanding of a growing number of critical pathways involved in breast cancer. These advances have led to the development of novel therapies that are being collectively known as molecularly targeted in order to highlight their specificity and their interference with key molecular events responsible for the malignant phenotype. Examples of approved targeted agents in breast cancer include agents directed against the human epidermal growth factor receptor 2 (HER2) such as trastuzumab and lapatinib and the anti-VEGF bevacizumab. In addition, there are classes of therapies under evaluation including novel anti-HER2 therapies, agents against other tyrosine kinases including Src and Insulin-Like Growth Factor Receptor agents interfering with critically important signalling pathways such as the PI3K/Akt/mTOR inhibitors and agents that promote apoptosis such as Parp inhibitors and others. The challenges that are being brought by these novel therapies are different from those being faced with conventional chemotherapy. They include the selection of appropriate dose and schedule, safety issues, selection of the patient population most likely to benefit and early readouts of clinical benefit. We will present these novel therapies and will analyse for each target the developmental status of some of the agents as well as target-specific challenges.
Insights
Novel molecularly targeted therapies are revolutionizing breast cancer treatment by interfering with key pathways. Challenges include optimal dosing, patient selection, and assessing clinical benefit for these advanced agents.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Significant advances in understanding breast cancer pathways have occurred.
- Novel molecularly targeted therapies have been developed to interfere with key molecular events driving cancer.
- Approved agents include anti-HER2 therapies (trastuzumab, lapatinib) and anti-VEGF (bevacizumab).
Purpose of the Study:
- To present novel molecularly targeted therapies for breast cancer.
- To analyze the developmental status of agents targeting specific pathways.
- To discuss target-specific challenges associated with these novel therapies.
Main Methods:
- Review of approved and investigational molecularly targeted agents in breast cancer.
- Analysis of therapies targeting HER2, tyrosine kinases (Src, IGF-R), PI3K/Akt/mTOR, and apoptosis pathways (PARP inhibitors).
- Evaluation of developmental status and target-specific challenges for novel agents.
Main Results:
- Several classes of targeted therapies are approved or under evaluation for breast cancer.
- Investigational agents target pathways including novel anti-HER2, Src, Insulin-Like Growth Factor Receptor, PI3K/Akt/mTOR, and PARP inhibitors.
- Novel therapies present unique challenges in dosing, scheduling, safety, patient selection, and clinical benefit assessment.
Conclusions:
- Molecularly targeted therapies represent a significant advancement in breast cancer treatment.
- Ongoing research and development are expanding the armamentarium of targeted agents.
- Addressing specific challenges is crucial for the successful clinical implementation of these novel therapies.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistent Cancers